-
公开(公告)号：US10912795B1
公开(公告)日：2021-02-09
申请号：US16850726
申请日：2020-04-16
发明人： John Maloney , Aruna Koganti , Phanesh Koneru
IPC分类号： A61K33/06 , A61K31/095 , A61K31/401 , A61K31/405 , A61K47/02 , A61K33/241 , A61K9/00 , A61K33/36 , A61K33/00 , A23L33/175 , A61K33/28 , A23L33/16 , A61K31/198 , A61K31/4172 , A61K31/191 , A61J1/14
摘要： The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
-
公开(公告)号：US10583155B1
公开(公告)日：2020-03-10
申请号：US16665702
申请日：2019-10-28
发明人： John Maloney , Aruna Koganti , Phanesh Koneru
IPC分类号： A61K33/06 , A61K33/241 , A61K31/401 , A23L33/16 , A23L33/175 , A61K31/405 , A61K31/095 , A61K9/00 , A61K33/00 , A61K47/02 , A61K31/191 , A61K31/198 , A61K31/4172 , A61K33/36 , A61K33/28 , A61J1/14
摘要： The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
-
公开(公告)号：US11679125B1
公开(公告)日：2023-06-20
申请号：US18067605
申请日：2022-12-16
发明人： John Maloney , Aruna Koganti , Phanesh Koneru
IPC分类号： A61K33/08 , A61K33/06 , A23L33/16 , A61K31/191 , A61K9/00 , A61K31/405 , A61K31/095 , A23L33/175 , A61K31/198 , A61K31/4172 , A61K31/401 , A61K33/28 , A61K33/241 , A61K33/36 , A61K33/00 , A61K47/02 , A61J1/14
CPC分类号： A61K33/06 , A23L33/16 , A23L33/175 , A61K9/0029 , A61K31/095 , A61K31/191 , A61K31/198 , A61K31/401 , A61K31/405 , A61K31/4172 , A61K33/00 , A61K33/241 , A61K33/28 , A61K33/36 , A61K47/02 , A23V2002/00 , A61J1/1412
摘要： The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
-
公开(公告)号：US10918662B1
公开(公告)日：2021-02-16
申请号：US16850973
申请日：2020-04-16
发明人： John Maloney , Aruna Koganti , Phanesh Koneru
IPC分类号： A61K33/06 , A61K31/095 , A61K31/401 , A61K31/405 , A61K47/02 , A61K33/241 , A61K9/00 , A61K33/36 , A61K33/00 , A23L33/175 , A61K33/28 , A23L33/16 , A61K31/198 , A61K31/4172 , A61K31/191 , A61J1/14
摘要： The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
-
公开(公告)号：US11648262B1
公开(公告)日：2023-05-16
申请号：US18067397
申请日：2022-12-16
发明人： John Maloney , Aruna Koganti , Phanesh Koneru
IPC分类号： A61K33/06 , A23L33/16 , A61K31/191 , A61K9/00 , A61K31/405 , A61K31/095 , A23L33/175 , A61K31/198 , A61K31/4172 , A61K31/401 , A61K33/28 , A61K33/241 , A61K33/36 , A61K33/00 , A61K47/02 , A61J1/14
CPC分类号： A61K33/06 , A23L33/16 , A23L33/175 , A61K9/0029 , A61K31/095 , A61K31/191 , A61K31/198 , A61K31/401 , A61K31/405 , A61K31/4172 , A61K33/00 , A61K33/241 , A61K33/28 , A61K33/36 , A61K47/02 , A23V2002/00 , A61J1/1412
摘要： The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
-
公开(公告)号：US10933089B1
公开(公告)日：2021-03-02
申请号：US16746028
申请日：2020-01-17
发明人： John Maloney , Aruna Koganti , Phanesh Koneru
IPC分类号： A61K33/06 , A61K31/191 , A23L33/16 , A61K31/198 , A61K31/095 , A61K33/28 , A61K33/00 , A61K31/401 , A61K31/405 , A61K33/241 , A61K47/02 , A61K31/4172 , A23L33/175 , A61K9/00 , A61K33/36 , A61J1/14
摘要： The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
-
公开(公告)号：US11826383B1
公开(公告)日：2023-11-28
申请号：US18332677
申请日：2023-06-09
发明人： John Maloney , Aruna Koganti , Phanesh Koneru
IPC分类号： A61K33/06 , A61K31/191 , A61K47/02 , A61K33/36 , A61K33/241 , A61K33/28 , A61K33/00 , A61K31/405 , A61K31/401 , A61K31/4172 , A61K9/00 , A23L33/175 , A23L33/16 , A61K31/198 , A61K31/095 , A61J1/14
CPC分类号： A61K33/06 , A23L33/16 , A23L33/175 , A61K9/0029 , A61K31/095 , A61K31/191 , A61K31/198 , A61K31/401 , A61K31/405 , A61K31/4172 , A61K33/00 , A61K33/241 , A61K33/28 , A61K33/36 , A61K47/02 , A23V2002/00 , A61J1/1412
摘要： The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
-
公开(公告)号：US11510942B1
公开(公告)日：2022-11-29
申请号：US17188922
申请日：2021-03-01
发明人： John Maloney , Aruna Koganti , Phanesh Koneru
IPC分类号： A61K31/4172 , A61K33/06 , A61K31/191 , A61K47/02 , A61K33/36 , A61K33/241 , A61K33/28 , A61K33/00 , A61K31/405 , A61K31/401 , A61K9/00 , A23L33/175 , A23L33/16 , A61K31/198 , A61K31/095 , A61J1/14
摘要： The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cysteine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
-
公开(公告)号：US11510941B1
公开(公告)日：2022-11-29
申请号：US17164263
申请日：2021-02-01
发明人： John Maloney , Aruna Koganti , Phanesh Koneru
IPC分类号： A61K31/4172 , A61K33/06 , A61K31/191 , A61K47/02 , A61K33/36 , A61K33/241 , A61K33/28 , A61K33/00 , A61K31/405 , A61K31/401 , A61K9/00 , A23L33/175 , A23L33/16 , A61K31/198 , A61K31/095 , A61J1/14
摘要： The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
-
公开(公告)号：US10905713B2
公开(公告)日：2021-02-02
申请号：US16773641
申请日：2020-01-27
发明人： John Maloney , Aruna Koganti , Phanesh Koneru
IPC分类号： A61K33/06 , A61K31/191 , A61K47/02 , A61K33/36 , A61K33/241 , A61K33/28 , A61K33/00 , A61K31/405 , A61K31/401 , A61K31/4172 , A61K9/00 , A23L33/175 , A23L33/16 , A61K31/198 , A61K31/095 , A61J1/14
摘要： The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.021 秒)
